title: Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines.
abstract: Mesothelioma is a malignant tumor of the serous surfaces in the thorax and abdomen, which has proved exceptionally resistant to treatment. A recent phase II trial of a high-dose methotrexate regime on 63 Norwegian patients has, however, achieved a response rate of 37%. Some responses have also been achieved using interferon (IFN)-gamma administered intrapleurally or recombinant (r) IFN-alpha administered subcutaneously. Our earlier in vitro sensitivity studies of mesothelioma cell lines showed that IFN augments the response to chemotherapeutic agents in mesothelioma. The aim of this study was to assess the response of four mesothelioma cell lines, derived from diffuse asbestos-related pleural malignant mesothelioma, to methotrexate alone and in combination with recombinant IFN-alpha and IFN-gamma. Anti-proliferative effects were assayed by vital dye exclusion. A combination of IFN-alpha and IFN-gamma consistently augmented the response of the cell lines to methotrexate, by as much as 75% for one cell line, although the response to the individual IFNs was variable. We were also able to compare the effects of natural IFN-beta with those of IFN-alpha and IFN-gamma. The IFN-beta sensitivity profile for each of the four cell lines was similar to that of IFN-alpha. In two cell lines, the combination of IFN-beta and IFN-gamma produced a similar effect to the IFN-alpha and IFN-gamma combination.
authors.affiliation: Finnish Institute of Occupational Health, Helsinki.
authors.forename: A
authors.initials: A
authors.lastname: Hand
authors.forename: K
authors.initials: K
authors.lastname: Pelin
authors.forename: K
authors.initials: K
authors.lastname: Mattson
authors.forename: K
authors.initials: K
authors.lastname: Linnainmaa
mesh_terms: D004347:Drug Interactions; D006801:Humans; D007364:Intercalating Agents / Q000494:pharmacology; D016898:Interferon-alpha / Q000494:pharmacology*; D016899:Interferon-beta / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D008654:Mesothelioma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008727:Methotrexate / Q000494:pharmacology; D008942:Mitoxantrone / Q000494:pharmacology; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D007364:Intercalating Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016899:Interferon-beta; D007371:Interferon-gamma; D008942:Mitoxantrone; D008727:Methotrexate